Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Treatment-Resistant Depression Market to Rising at a CAGR of 15% Driven by Recent Advancements in Clinical Trials

This image opens in the lightbox

News provided by

DelveInsight Business Research, LLP

11 Mar, 2021, 16:30 GMT

Share this article

Share toX

Share this article

Share toX

Advances in the understanding of Treatment-Resistant Depression pathophysiology have yielded an array of antidepressant agents & improvements in treatment

LAS VEGAS, March 11, 2021 /PRNewswire/ -- DelveInsight's "Treatment-Resistant Depression (TRD) Market" report provides a thorough comprehension of the Treatment-Resistant Depression, historical and forecasted epidemiology, and the TRD market trends in the 7MM [the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan]. The Treatment-Resistant Depression market report also proffers an analysis of recent Treatment-Resistant Depression treatment algorithm/practice, market drivers, market barriers, and unmet medical needs. 

Some of the vital points of the Treatment-Resistant Depression Market Research Report

  • The FDA approved SYMBYAX for acute treatment of TRD and depressive episodes associated with Bipolar Disorder in adults in March 2009. 
  • In March 2019, the FDA approved Spravato-non-competitive N-methyl D-aspartate (NMDA) receptor antagonist, in conjunction with an oral antidepressant, for the TRD treatment in adults. It is the first-ever approved NMDA therapy for TRD. 
  • Dominant players such as Eli Lilly and Company, Johnson& Johnson,  Janssen Pharmaceuticals, Axsome Therapeutics, Alkermes, Allergan/ Gedeon Richter, Minerva Neurosciences, Acadia Pharmaceuticals, Novartis, Celon Pharma, COMPASS Pathways, Relmada Therapeutics, Vistagen Therapeutics, OcuNexus Therapeutics, Eyevance Pharmaceuticals, and others involved in developing targeted TRD therapeutics.
  • The Treatment-Resistant Depression market is expected to show positive growth, mainly attributed to an increased number of TRD cases and the expected launch of therapies such as AXS-05, ALKS-5461, Cariprazine, Seltorexant, Pimavanserin, MIJ821, Esketamine DPI, Psilocybin, REL-1017, and others.
  • With a novel mechanism of action, these therapies may change the Treatment-Resistant Depression treatment regimen by 2030.

For further information on Market Impact by Therapies, visit: Treatment-Resistant Depression (TRD) Market Trends

Treatment-Resistant Depression (TRD) is a major depressive disorder (MDD) that does not respond to traditional and first-line therapeutic options. MDD is a mood disorder and causes a continuous feeling of sadness and loss of interest that can interfere with day-to-day life.

According to DelveInsight's analysts, the total diagnosed Treatment-Resistant Depression prevalent population in 7MM was estimated to be 4,464,781 cases in 2017. The females appear to have a predisposition to Treatment-Resistant Depression, which is why a higher percentage of prevalence was observed in females than males in the United States.

The TRD Market Report provides historical as well as forecasted epidemiological analysis segmented into: 

  • Total diagnosed prevalent cases 
  • Gender-specific cases 
  • Age-specific cases 

Get a sample copy of this report: Treatment-Resistant Depression Market Landscape

Treatment-Resistant Depression Treatment Market 

The TRD therapeutic market size is mainly regarded by the management options involving pharmacologic treatment options and non-pharmacological therapies. 

Pharmacologic treatment options comprise switching, combination, and potentiation strategy among the commonly used antidepressant drugs. The majority of the available antidepressants such as Selective Serotonin Reuptake Inhibitor (SSRI), Dual serotonin and norepinephrine reuptake inhibitors (SNRIs), Tricyclic antidepressant, Irreversible, non-selective monoamine oxidase inhibitors (MAOIs), α2-antagonists, Agomelatine, Tianeptine are used for Treatment-Resistant Depression Treatment.

Switching is recommended when there is no response or low tolerance to the initial treatment, inadequate response to the newly introduced treatment. Selective Serotonin Reuptake Inhibitor (SSRI) is considered a first-line treatment, nevertheless of the clinical severity. When there is no response from SSRI, norepinephrine reuptake inhibitors (SNRIs) are taken into consideration. But, there is no response from SNRIs; the next approach is a tricyclic antidepressant. 

The combination strategy is only recommended in partial response cases after 4 to 6 weeks of adequate treatment. In the first-line, the recommended strategies comprise combinations such as SSRI + α2 antagonist, SNRI + α2 antagonist, and Tricyclic antidepressant + α2-antagonist. In the second-line treatment, an association between SSRIs, SNRIs, or tricyclic antidepressants and agomelatine can be proposed.

Non-pharmacological therapies involve electroconvulsive therapy (ECT), Repetitive transcranial magnetic stimulation (rTMS), and Vagus nerve stimulation (VNS). Along with this, two alternative forms of psychotherapy comprise majorly cognitive-behavioural therapy (CBT) and interpersonal therapy (IPT).

Despite an increasing variety of choices for the treatment of TRD, this condition continues to be universally undefined and represents an area of unmet medical need. There are only a few known approved TRD pharmacological agents. So, various biotechnological companies are working towards the development of targeted TRD therapeutics. 

TRD Emerging Therapies Along with Key Players 

  • ALKS 5461: Alkermes
  • Cariprazine: Allergan/Gedeon Richter
  • Pimavanserin: ACADIA Pharmaceuticals
  • AXS-05: Axsome Therapeutics
  • Seltorexant: Johnson and Johnson/Minerva Neurosciences
  • Esketamine DPI: Celon Pharma
  • REL-1017: Relmada Therapeutics
  • AV-101: VistaGen Therapeutics
  • MIJ821: Novartis
  • Psilocybin (COMP360): COMPASS Pathways

And several others.

Final comments on Treatment-Resistant Depression Market Growth 

Treatment-Resistant Depression Market Drivers 

  • Research and Development - Increase in the understanding of pathophysiology and the development of novel therapeutic compounds have emerged.
  • Development of Pioneering Therapies - Various drugs are in the trial that can help in the growth of the TRD market in the future. Next-generation SSRI antidepressants are being developed with the promise of better tolerability. Demand for the new antidepressant agents leads to an increase in research activities, and researchers are focusing on the various targets such as NMDA and others.
  • Retainment of Current Management Strategies and Refined Clinical Trial Design 

Treatment-Resistant Depression Market Barriers 

  • Economic Burden - The burden of depression is increasing despite advancements in treatments. Several factors contribute to the economic burden, including the prevalence, rate, degree of impairment, and lesser remission.
  • Variable Treatment Response - The disease is itself treatment-resistant which encourages increasingly risky treatment interventions that are likely to affect patients negatively Treatment options are limited and also with increased toxicity with higher dosages and combination regimens.
  • Commercial Challenges - Stringent policies for regulatory approvals can be a threat to the TRD market. Gaining market access and reimbursement further complicates it.

Scope of the Treatment-Resistant Depression Market Insight Report 

  • Geography Covered: 7MM - The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan.
  • Study Period: 3-year historical and 11-year forecasted analysis (2017-2030).
  • Treatment-Resistant Depression Markets Segmentation: By Geographies and By Treatment-Resistant Depression Therapies (Historical and Forecasted, Current and Upcoming) 
  • Dominant Market Companies investigating its candidates for Treatment-Resistant Depression: Eli Lilly and Company, Johnson& Johnson,  Janssen Pharmaceuticals, Axsome Therapeutics, Alkermes, Allergan/ Gedeon Richter, Minerva Neurosciences, Acadia Pharmaceuticals, Novartis, Celon Pharma, COMPASS Pathways, Relmada Therapeutics, Vistagen Therapeutics, OcuNexus Therapeutics, Eyevance Pharmaceuticals, and several others.
  • Analysis: Comparative and conjoint analysis of emerging therapies.
  • Case Studies
  • KOL's Views
  • Analyst's View

Request for a Webex demo of the report @ TRD Treatment Market Size

Table of Contents 

1

Key Insights on Treatment-Resistant Depression (TRD)

2

Treatment-Resistant Depression Market Overview at a Glance 

3

Organizations

4

Executive Summary

5

Disease Overview: Treatment Resistant Depression

6

TRD Epidemiology and Patient Population

7

The United States

8

EU5 Countries TRD Epidemiology

8.1.

Germany

8.2.

France

8.3.

Italy

8.4.

Spain

8.5.

The United Kingdom

9

Japan TRD Epidemiology

10

Treatment Resistant Depression Current Treatment Practices

11

Treatment-Resistant Depression Unmet Needs

12

Treatment Resistant Depression Marketed drugs

12.1

Symbyax: Eli Lilly and Company

12.2

Spravato: Johnson& Johnson

13

Treatment Resistant Depression Emerging Therapies

13.1

Key cross competition

13.2

ALKS 5461: Alkermes

13.3

Cariprazine: Allergan/Gedeon Richter's

13.4

Pimavanserin: ACADIA Pharmaceuticals

13.5

AXS-05: Axsome Therapeutics

13.6

Seltorexant: Johnson and Johnson/Minerva Neurosciences

13.7

Esketamine DPI: Celon Pharma

13.8

REL-1017: Relmada Therapeutics

13.9

AV-101: VistaGen Therapeutics

13.10

MIJ821: Novartis

13.11

Psilocybin (COMP360): COMPASS Pathways

14

Other TRD potential therapies

14.1

Rapastinel: Allergan

14.2

PH10 Nasal Spray: VistaGen Therapeutics

15

7MM Treatment-Resistant Depression Market Analysis

16

TRD Market Outlook by Country

17

The United States Treatment-Resistant Depression Market Outlook

18

EU-5 Treatment-Resistant Depression Market Outlook

18.1

Germany Market Size

18.2

France Market Size

18.3

Italy Market Size

18.4

Spain Market Size

18.5

The United Kingdom Market Size

19

Japan Treatment-Resistant Depression Market Outlook

20

Treatment-Resistant Depression Market Drivers

21

Treatment-Resistant Depression Market Barriers

22

Treatment-Resistant Depression SWOT Analysis

23

Treatment-Resistant Depression Market Access and Reimbursement

24

Case Studies

25

KOL Views

26

Appendix

27

DelveInsight Capabilities

28

Disclaimer

29

About DelveInsight

Browse full report with detailed TOC with charts, figures, tables @ Treatment-Resistant Depression Market Size Report 

View Related Reports       

  • Treatment-resistant depression Epidemiology Forecast Analysis 

DelveInsight's Treatment-resistant depression - Epidemiology Forecast 2030 report delivers an in-depth understanding of the historical, and forecasted epidemiology of the disease in 7MM.

  • Treatment-Resistant Depression Pipeline Analysis 

Treatment-Resistant Depression Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Treatment-Resistant Depression market.

  • Bipolar Depression Market Analysis 

DelveInsight's Bipolar Disorder (Manic Depression) - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and in-depth understanding.

  • Postpartum Depression Market Analysis 

DelveInsight's Postpartum Depression - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and in-depth understanding.

  • Bipolar Disorder (Manic Depression) Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2020

Bipolar Disorder (Manic Depression) - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2020 " report by DelveInsight offers comprehensive insights on marketed and Phase III products for Bipolar Disorder (Manic Depression).

  • Major Depressive Disorder Market 

DelveInsight's Major Depressive Disorder - Market Insights, Epidemiology, and Market Forecast - 2030 report provides a detailed overview of the disease and an in-depth understanding of historical and forecasted epidemiology.

  • VCF Treatment Devices Market Insights, Competitive Landscape, and Market Forecast Analysis 

VCF Treatment Devices Market Insights, Competitive Landscape and Market Forecast-2025 report delivers an in-depth understanding of VCF Treatment Devices. 

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. 

Contact Us:

Shruti Thakur 
info@delveinsight.com 
+1(919)321-6187 
www.delveinsight.com 

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg

Modal title

Also from this source

Comprehensive Lewy Body Dementia Market Analysis of Evolving Trends and Anticipated Growth Trajectory During the Forecast Period (2025-2034) | DelveInsight

Comprehensive Lewy Body Dementia Market Analysis of Evolving Trends and Anticipated Growth Trajectory During the Forecast Period (2025-2034) | DelveInsight

Lewy body dementia (LBD) is a progressive neurological condition characterized by the accumulation of abnormal alpha-synuclein protein in the brain....

Anti-GPC3 Therapies Market Gains Traction with Key Players Advancing Pipeline for Hepatocellular Carcinoma, Non-Small Cell Lung Cancer, Gastric Cancer, and Others | DelveInsight

Anti-GPC3 Therapies Market Gains Traction with Key Players Advancing Pipeline for Hepatocellular Carcinoma, Non-Small Cell Lung Cancer, Gastric Cancer, and Others | DelveInsight

DelveInsight's Anti-GPC3 Targeted Therapies Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive...

More Releases From This Source

Explore

Medical Pharmaceuticals

Medical Pharmaceuticals

Health Care & Hospitals

Health Care & Hospitals

Publishing & Information Services

Publishing & Information Services

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.